Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry

• Giulia RendaUniversity of Chieti-Pescara
• Ladislav PecenCzech Academy of Sciences, Institute of Computer Science
• Giuseppe PattiUniversità degli Studi del Piemonte Orientale “Amedeo Avogadro”
• Fabrizio RicciUniversity of Chieti-Pescara
• Dipak KotechaUniversity Hospitals Birmingham NHS Foundation Trust
• Jolanta Maria Siller-MatulaPoznan University of Medical Sciences
• Renate B. SchnabelUniversität Hamburg
• Rolf WachterUniversity Hospital Leipzig
• Jean‐Marc SellalCentre Hospitalier Régional et Universitaire de Nancy
• Miklós RohlaWilhelminen Hospital
• Markus LucernaDaiichi Sankyo (Germany)
• Kurt HuberSigmund Freud Privatuniversität Wien
• Freek W.A. Verheugt
• José Luis ZamoranoHospital Universitario Ramón y Cajal
• Bernd BrüggenjürgenSteinbeis University Berlin
• Harald DariusVivantes Klinikum
• Mattias Francis DuytschaeverAZ Sint-Jan
• Jean‐Yves Le HeuzeyUniversité Paris Descartes
• RICHARD JOHN SCHILLINGLondon Bridge Hospital
• Paulus F. KirchhofUniversity Hospitals Birmingham NHS Foundation Trust
• Raffaele De CaterinaUniversity of Pisa